Retatrutide vs Mounjaro: What's the Difference?

Retatrutide vs Mounjaro

As interest in next-generation weight management therapies continues to grow, one of the most common questions is "Is Retatrutide better than Mounjaro?"

Both medicines have attracted significant attention because they target hormones involved in appetite regulation, blood sugar control, and metabolism. However, there are important differences between them, particularly in how they work and where they currently stand in clinical development.

Retatrutide remains an investigational medicine, while Mounjaro (tirzepatide) has received approval in several countries for specific indications.

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational medicine developed by Eli Lilly.

It is known as a triple receptor agonist because it activates:

• GLP-1 receptors

• GIP receptors

• Glucagon receptors

Researchers are studying whether activating all three pathways may improve weight management and metabolic health beyond therapies that target fewer receptors.

Retatrutide is currently undergoing Phase 3 clinical trials and has not been approved for routine clinical use in the United Kingdom.

What Is Mounjaro?

Mounjaro contains tirzepatide, another medicine developed by Eli Lilly.

Unlike Retatrutide, Mounjaro activates:

• GLP-1 receptors

• GIP receptors

Because it targets two hormone pathways instead of three, it is known as a dual receptor agonist.

Mounjaro has been approved in several countries for specific medical indications, subject to local regulatory decisions.

How Do They Work?

Although both medicines influence appetite and metabolism, Retatrutide includes one additional mechanism.

Retatrutide

• GLP-1 activation

• GIP activation

• Glucagon activation

Mounjaro

• GLP-1 activation

• GIP activation

Researchers believe glucagon receptor activation may contribute to increased energy expenditure and fat metabolism, which is one reason Retatrutide has generated considerable scientific interest.

Is Retatrutide Better Than Mounjaro?

At this stage, there is no definitive answer.

Retatrutide has shown encouraging results in clinical research, while Mounjaro has demonstrated effectiveness in large clinical trials and is already approved for specific uses in several regions.

Because the medicines have been studied in different clinical trials involving different participant groups, it is not possible to conclude that one is superior based solely on published study results.

Head-to-head clinical comparisons would be needed to answer this question directly.

Clinical Research

Retatrutide has been studied in adults with obesity and overweight.

Published research has reported substantial average reductions in body weight over 48 weeks, leading to continued Phase 3 investigation.

Mounjaro has also demonstrated significant weight reduction in clinical studies and has progressed through regulatory approval processes for certain indications.

Both medicines continue to be evaluated through ongoing research.

Retatrutide vs Mounjaro Comparison

FeatureRetatrutideMounjaroDeveloperEli LillyEli LillyHormone TargetsGLP-1, GIP, GlucagonGLP-1, GIPMechanismTriple receptor agonistDual receptor agonistAdministrationOnce-weekly injection (clinical studies)Once-weekly injectionCurrent UK StatusInvestigationalApproved for specific indications

Can You Switch from Mounjaro to Retatrutide?

Some people ask whether they can move from Mounjaro to Retatrutide.

Because Retatrutide remains investigational, treatment decisions depend on approved medical guidance and, where applicable, eligibility for authorised clinical research.

Anyone considering changes to a prescribed treatment should discuss their individual circumstances with a qualified healthcare professional.

Which Medicine Is Right?

The answer depends on many factors, including:

• Individual medical history.

• Treatment goals.

• Current evidence.

• Regulatory approval.

• Healthcare professional recommendations.

As Retatrutide is still under investigation, researchers continue to evaluate where it may fit alongside existing therapies if approved in the future.

Frequently Asked Questions

Is Retatrutide better than Mounjaro?

Current evidence does not allow a definitive conclusion because the medicines have not been directly compared in large head-to-head clinical trials.

Is Retatrutide the same as Mounjaro?

No. Retatrutide activates three hormone receptors (GLP-1, GIP, and glucagon), while Mounjaro activates two (GLP-1 and GIP).

Which medicine has three hormone targets?

Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors.

Is Mounjaro approved in the UK?

Mounjaro has been approved for specific indications in the UK. Retatrutide remains investigational and has not been approved for routine clinical use.

Can you take Retatrutide after Mounjaro?

Because Retatrutide is still investigational, any treatment decisions should be made with a qualified healthcare professional and in accordance with approved guidance.

Final Thoughts

Retatrutide and Mounjaro represent important advances in obesity and metabolic health research, but they are at different stages of development.

Retatrutide's triple-receptor mechanism has generated significant scientific interest, while Mounjaro is an established therapy for approved indications. Ongoing clinical trials will provide a clearer understanding of Retatrutide's long-term safety, effectiveness, and potential role in future treatment options.

For readers interested in learning more, explore our guides on Retatrutide clinical trials, Retatrutide side effects, Retatrutide dosage research, Retatrutide UK availability, and the latest developments in metabolic health research.